Piramal Pharma Limited Reports Strong Growth in Q2 and H1 FY27

Piramal Pharma Limited has reported a significant increase in revenue and profit for the second quarter and half-year ending September 30, 2026. The company achieved a 28% year-on-year revenue growth in Q2, with a cumulative 23% rise for the first half of FY27. Notably, the EBITDA surged by 72% in both Q2 and H1, demonstrating improved profitability margins driven by higher capacity utilization and efficient cost management.

Particularly, the company's Contract Development and Manufacturing Organization (CDMO) division saw a 36% growth in Q2, contributing significantly to the overall performance. The Complex Hospital Generics (CHG) and Piramal Consumer Healthcare divisions also showed year-on-year improvements of 32% and 13%, respectively, highlighting broad-based strength across all segments.

This robust financial performance aligns with the company's strategic initiatives, including product innovation and operational optimization. Consequently, Piramal Pharma has upgraded its FY27 outlook, forecasting a 19% to 20% growth, backed by a strong order book and ongoing engagement with new and existing customers.